Blumenthal M, ed. The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. Trans. S. Klein. Boston, MA: American Botanical Council, 1998.

Misra MC, Parshad R. Randomized clinical trial of micronized flavonoids in the early control of bleeding from acute internal haemorrhoids. Br J Surgery 2000;87:868-72. View abstract.

Cospite M. Double-blind, placebo-controlled evaluation of clinical activity and safety of Daflon 500 mg in the treatment of acute hemorrhoids. Angiology 1994;45:566-73. View abstract.

Di Carlo G, Mascolo N, Izzo AA, Capasso F. Flavonoids: Old and new aspects of a class of natural therapeutic drugs. Life Sci 1999;65:337-53. View abstract.

Koyuncu H, Berkarda B, Baykut F, et al. Preventive effect of hesperidin against inflammation in CD-1 mouse skin caused by tumor promoter. Anticancer Res 1999;19:3237-41.

Craig WJ. Health-promoting properties of common herbs. Am J Clin Nutr 1999;70:491-9. View abstract.

Middleton E. Some biological properties of plant flavonoids. Ann Allergy 1988;61:53-7. View abstract.

Ho Y, Tan M, Seow-Choen F. Micronized purified flavonidic fraction compared favorably with rubber band ligation and fiber alone in the management of bleeding hemorrhoids. Dis Colon Rectum 2000;43:66-9. View abstract.

Beltramino R, Penenory A, Buceta AM. An open-label, randomized multicenter study comparing the efficacy and safety of Cyclo 3 Fort versus hydroxyethyl rutoside in chronic venous lymphatic insufficiency. Angiology 2000;51:535-44.. View abstract.

Cappelli R, Nicora M, Di Perri T. Use of extract of Ruscus aculeatus in venous disease in the lower limbs. Drugs Exp Clin Res 1988;14:277-83. View abstract.

Pecking AP, Fevrier B, Wargon C, Pillion G. Efficacy of Daflon 500 mg in the treatment of lymphedema (secondary to conventional therapy of breast cancer). Angiology 1997;48:93-8.. View abstract.

Guilhou JJ, Dereure O, Marzin L, et al. Efficacy of Daflon 500 mg in venous leg ulcer healing: a double-blind, randomized, controlled versus placebo trial in 107 patients. Angiology 1997;48:77-85.. View abstract.

Bouaziz, N., Michiels, C., Janssens, D., Berna, N., Eliaers, F., Panconi, E., and Remacle, J. Effect of Ruscus extract and hesperidin methylchalcone on hypoxia-induced activation of endothelial cells. Int Angiol. 1999;18(4):306-312. View abstract.

Beltramino, R., Penenory, A., and Buceta, A. M. An open-label, randomised multicentre study comparing the efficacy and safety of CYCLO 3 FORT versus hydroxyethyl rutoside in chronic venous lymphatic insufficiency. Int Angiol. 1999;18(4):337-342. View abstract.

Boyle, P., Diehm, C., and Robertson, C. Meta-analysis of clinical trials of Cyclo 3 Fort in the treatment of chronic venous insufficiency. Int Angiol. 2003;22(3):250-262. View abstract.

Cluzan, R. V., Alliot, F., Ghabboun, S., and Pascot, M. Treatment of secondary lymphedema of the upper limb with CYCLO 3 FORT. Lymphology 1996;29(1):29-35. View abstract.

Cesarone, M. R., Belcaro, G., Rohdewald, P., Pellegrini, L., Ledda, A., Vinciguerra, G., Ricci, A., Gizzi, G., Ippolito, E., Fano, F., Dugall, M., Acerbi, G., Cacchio, M., Di Renzo, A., Hosoi, M., Stuard, S., and Corsi, M. Comparison of Pycnogenol and Daflon in treating chronic venous insufficiency: a prospective, controlled study. Clin Appl Thromb.Hemost. 2006;12(2):205-212. View abstract.

Ameer, B., Weintraub, R. A., Johnson, J. V., Yost, R. A., and Rouseff, R. L. Flavanone absorption after naringin, hesperidin, and citrus administration. Clin Pharmacol Ther 1996;60(1):34-40. View abstract.

Jantet, G. Chronic venous insufficiency: worldwide results of the RELIEF study. Reflux assEssment and quaLity of lIfe improvEment with micronized Flavonoids. Angiology 2002;53(3):245-256. View abstract.

Lyseng-Williamson, K. A. and Perry, C. M. Micronised purified flavonoid fraction: a review of its use in chronic venous insufficiency, venous ulcers and haemorrhoids. Drugs 2003;63(1):71-100. View abstract.

Manach, C., Morand, C., Gil-Izquierdo, A., Bouteloup-Demange, C., and Remesy, C. Bioavailability in humans of the flavanones hesperidin and narirutin after the ingestion of two doses of orange juice. Eur.J.Clin.Nutr. 2003;57(2):235-242. View abstract.

Chiba, H., Uehara, M., Wu, J., Wang, X., Masuyama, R., Suzuki, K., Kanazawa, K., and Ishimi, Y. Hesperidin, a citrus flavonoid, inhibits bone loss and decreases serum and hepatic lipids in ovariectomized mice. J.Nutr. 2003;133(6):1892-1897. View abstract.

Sakata, K., Hirose, Y., Qiao, Z., Tanaka, T., and Mori, H. Inhibition of inducible isoforms of cyclooxygenase and nitric oxide synthase by flavonoid hesperidin in mouse macrophage cell line. Cancer Lett. 9-25-2003;199(2):139-145. View abstract.

BOOTH, A. N., JONES, F. T., and DeEDS, F. Metabolic fate of hesperidin, eriodictyol, homoeridictyol, and diosmin. J.Biol.Chem. 1958;230(2):661-668. View abstract.

Fenton, J. I. and Hord, N. G. Flavonoids promote cell migration in nontumorigenic colon epithelial cells differing in Apc genotype: implications of matrix metalloproteinase activity. Nutr.Cancer 2004;48(2):182-188. View abstract.

Jung, U. J., Lee, M. K., Jeong, K. S., and Choi, M. S. The hypoglycemic effects of hesperidin and naringin are partly mediated by hepatic glucose-regulating enzymes in C57BL/KsJ-db/db mice. J.Nutr. 2004;134(10):2499-2503. View abstract.

Cesarone, M. R., Belcaro, G., Pellegrini, L., Ledda, A., Di Renzo, A., Vinciguerra, G., Ricci, A., Gizzi, G., Ippolito, E., Fano, F., Dugall, M., Acerbi, G., and Cacchio, M. HR, 0-(beta-hydroxyethyl)-rutosides, in comparison with diosmin+hesperidin in chronic venous insufficiency and venous microangiopathy: an independent, prospective, comparative registry study. Angiology 2005;56(1):1-8. View abstract.

Fernandez, S. P., Wasowski, C., Paladini, A. C., and Marder, M. Synergistic interaction between hesperidin, a natural flavonoid, and diazepam. Eur.J.Pharmacol. 4-11-2005;512(2-3):189-198. View abstract.

Mlakar, B. and Kosorok, P. Flavonoids to reduce bleeding and pain after stapled hemorrhoidopexy: a randomized controlled trial. Wien.Klin.Wochenschr. 2005;117(15-16):558-560. View abstract.

Cesarone, M. R., Belcaro, G., Pellegrini, L., Ledda, A., Vinciguerra, G., Ricci, A., Di Renzo, A., Ruffini, I., Gizzi, G., Ippolito, E., Fano, F., Dugall, M., Acerbi, G., Cornelli, U., Hosoi, M., and Cacchio, M. Venoruton vs Daflon: evaluation of effects on quality of life in chronic venous insufficiency. Angiology 2006;57(2):131-138. View abstract.

Miwa, Y., Mitsuzumi, H., Sunayama, T., Yamada, M., Okada, K., Kubota, M., Chaen, H., Mishima, Y., and Kibata, M. Glucosyl hesperidin lowers serum triglyceride level in hypertriglyceridemic subjects through the improvement of very low-density lipoprotein metabolic abnormality. J Nutr Sci Vitaminol.(Tokyo) 2005;51(6):460-470. View abstract.

Hosseinimehr, S. J. and Nemati, A. Radioprotective effects of hesperidin against gamma irradiation in mouse bone marrow cells. Br.J.Radiol. 2006;79(941):415-418. View abstract.

Yamada, M., Tanabe, F., Arai, N., Mitsuzumi, H., Miwa, Y., Kubota, M., Chaen, H., and Kibata, M. Bioavailability of glucosyl hesperidin in rats. Biosci.Biotechnol.Biochem. 2006;70(6):1386-1394. View abstract.

Kim, J. Y., Jung, K. J., Choi, J. S., and Chung, H. Y. Modulation of the age-related nuclear factor-kappaB (NF-kappaB) pathway by hesperetin. Aging Cell 2006;5(5):401-411. View abstract.

Uehara, M. [Prevention of osteoporosis by foods and dietary supplements. Hesperidin and bone metabolism]. Clin.Calcium 2006;16(10):1669-1676. View abstract.

Kanaze, F. I., Bounartzi, M. I., Georgarakis, M., and Niopas, I. Pharmacokinetics of the citrus flavanone aglycones hesperetin and naringenin after single oral administration in human subjects. Eur.J.Clin.Nutr. 2007;61(4):472-477. View abstract.

Jin, Y. R., Han, X. H., Zhang, Y. H., Lee, J. J., Lim, Y., Chung, J. H., and Yun, Y. P. Antiplatelet activity of hesperetin, a bioflavonoid, is mainly mediated by inhibition of PLC-gamma2 phosphorylation and cyclooxygenase-1 activity. Atherosclerosis 2007;194(1):144-152. View abstract.

Gardana, C., Guarnieri, S., Riso, P., Simonetti, P., and Porrini, M. Flavanone plasma pharmacokinetics from blood orange juice in human subjects. Br.J.Nutr. 2007;98(1):165-172. View abstract.

Pokrovsky, A. V., Saveljev, V. S., Kirienko, A. I., Bogachev, V. Y., Zolotukhin, I. A., Sapelkin, S. V., Shvalb, P. G., Zhukov, B. N., Vozlubleny, S. I., Sabelnikov, V. V., Voskanian, Y. E., Katelnitsky, I. I., Burleva, E. P., and Tolstikhin, V. Y. Surgical correction of varicose vein disease under micronized diosmin protection (results of the Russian multicenter controlled trial DEFANS). Angiol.Sosud.Khir. 2007;13(2):47-55. View abstract.

Loscalzo, L. M., Wasowski, C., Paladini, A. C., and Marder, M. Opioid receptors are involved in the sedative and antinociceptive effects of hesperidin as well as in its potentiation with benzodiazepines. Eur.J.Pharmacol. 2-12-2008;580(3):306-313. View abstract.

Yanez, J. A., Remsberg, C. M., Miranda, N. D., Vega-Villa, K. R., Andrews, P. K., and Davies, N. M. Pharmacokinetics of selected chiral flavonoids: hesperetin, naringenin and eriodictyol in rats and their content in fruit juices. Biopharm.Drug Dispos. 2008;29(2):63-82. View abstract.

Hwang, S. L. and Yen, G. C. Neuroprotective effects of the citrus flavanones against H2O2-induced cytotoxicity in PC12 cells. J.Agric.Food Chem. 2-13-2008;56(3):859-864. View abstract.

Kometani, T., Fukuda, T., Kakuma, T., Kawaguchi, K., Tamura, W., Kumazawa, Y., and Nagata, K. Effects of alpha-glucosylhesperidin, a bioactive food material, on collagen-induced arthritis in mice and rheumatoid arthritis in humans. Immunopharmacol.Immunotoxicol. 2008;30(1):117-134. View abstract.

Yamamoto, M., Suzuki, A., Jokura, H., Yamamoto, N., and Hase, T. Glucosyl hesperidin prevents endothelial dysfunction and oxidative stress in spontaneously hypertensive rats. Nutrition 2008;24(5):470-476. View abstract.

Pradeep, K., Park, S. H., and Ko, K. C. Hesperidin a flavanoglycone protects against gamma-irradiation induced hepatocellular damage and oxidative stress in Sprague-Dawley rats. Eur.J.Pharmacol. 6-10-2008;587(1-3):273-280. View abstract.

Aliev, S. A., Ibishov, K. G., and Aliev, E. S. [Certain aspects of pathogenesis of hemorheological and trophic disturbances and their pharmacological correction in patients with chronic venous insufficiency]. Vestn.Khir.Im I.I.Grek. 2008;167(2):39-43. View abstract.

Li, Y. M., Li, X. M., Li, G. M., Du, W. C., Zhang, J., Li, W. X., Xu, J., Hu, M., and Zhu, Z. In vivo pharmacokinetics of hesperidin are affected by treatment with glucosidase-like BglA protein isolated from yeasts. J.Agric.Food Chem. 7-23-2008;56(14):5550-5557. View abstract.

Brett, G. M., Hollands, W., Needs, P. W., Teucher, B., Dainty, J. R., Davis, B. D., Brodbelt, J. S., and Kroon, P. A. Absorption, metabolism and excretion of flavanones from single portions of orange fruit and juice and effects of anthropometric variables and contraceptive pill use on flavanone excretion. Br.J.Nutr. 2009;101(5):664-675. View abstract.

Guex, J. J., Enrici, E., Boussetta, S., Avril, L., Lis, C., and Taieb, C. Correlations between ankle circumference, symptoms, and quality of life demonstrate the clinical relevance of minimal leg swelling reduction: results of a study in 1,036 Argentinean patients. Dermatol.Surg. 2008;34(12):1666-1675. View abstract.

Iqbal, M. F. and Zhu, W. Y. Bioactivation of flavonoid diglycosides by chicken cecal bacteria. FEMS Microbiol.Lett. 2009;295(1):30-41. View abstract.

Saha, R. K., Takahashi, T., and Suzuki, T. Glucosyl hesperidin prevents influenza a virus replication in vitro by inhibition of viral sialidase. Biol.Pharm.Bull. 2009;32(7):1188-1192. View abstract.

Kumar, P. and Kumar, A. Protective effect of hesperidin and naringin against 3-nitropropionic acid induced Huntington's like symptoms in rats: possible role of nitric oxide. Behav.Brain Res. 1-5-2010;206(1):38-46. View abstract.

El-Readi, M. Z., Hamdan, D., Farrag, N., El-Shazly, A., and Wink, M. Inhibition of P-glycoprotein activity by limonin and other secondary metabolites from Citrus species in human colon and leukaemia cell lines. Eur.J.Pharmacol. 1-25-2010;626(2-3):139-145. View abstract.

Akiyama, S., Katsumata, S., Suzuki, K., Nakaya, Y., Ishimi, Y., and Uehara, M. Hypoglycemic and hypolipidemic effects of hesperidin and cyclodextrin-clathrated hesperetin in Goto-Kakizaki rats with type 2 diabetes. Biosci.Biotechnol.Biochem. 2009;73(12):2779-2782. View abstract.

Cospite, M. and Dominici, A. Double blind study of the pharmacodynamic and clinical activities of 5682 SE in venous insufficiency. Advantages of the new micronized form. Int Angiol. 1989;8(4 Suppl):61-65. View abstract.

Ho, Y. H., Foo, C. L., Seow-Choen, F., and Goh, H. S. Prospective randomized controlled trial of a micronized flavonidic fraction to reduce bleeding after haemorrhoidectomy. Br J Surg. 1995;82(8):1034-1035. View abstract.

Amato, C. Advantage of a micronized flavonoidic fraction (Daflon 500 mg) in comparison with a nonmicronized diosmin. Angiology 1994;45(6 Pt 2):531-536. View abstract.

Godeberge, P. Daflon 500 mg in the treatment of hemorrhoidal disease: a demonstrated efficacy in comparison with placebo. Angiology 1994;45(6 Pt 2):574-578. View abstract.

Galley, P. and Thiollet, M. A double-blind, placebo-controlled trial of a new veno-active flavonoid fraction (S 5682) in the treatment of symptomatic capillary fragility. Int Angiol. 1993;12(1):69-72. View abstract.

Buckshee, K., Takkar, D., and Aggarwal, N. Micronized flavonoid therapy in internal hemorrhoids of pregnancy. Int J Gynaecol Obstet 1997;57(2):145-151. View abstract.

Guilhou, J. J., Fevrier, F., Debure, C., Dubeaux, D., Gillet-Terver, M. N., Guillot, B., Levesque, H., Marzin, L., Mignot, J., Ouvry, P., Pillion, G., Van, Landuyt H., Zuccarelli, F., and Nicolaides, A. N. Benefit of a 2-month treatment with a micronized, purified flavonoidic fraction on venous ulcer healing. A randomized, double-blind, controlled versus placebo trial. Int.J.Microcirc.Clin.Exp. 1997;17 Suppl 1:21-26. View abstract.

Kim, D. H., Jung, E. A., Sohng, I. S., Han, J. A., Kim, T. H., and Han, M. J. Intestinal bacterial metabolism of flavonoids and its relation to some biological activities. Arch Pharm.Res. 1998;21(1):17-23. View abstract.

Rizk, S. M and Sabri, N. A. Evaluation of Clinical Activity and Safety of Dalfon® 500mg in Type 2 Diabetic Femal Patients. Saudi Pharmacetical Journal 3-17-2009;199-209.

Chassignolle, J. F., Amiel, M., Lanfranchi, G., and et al. Activité thérapeutique de Daflon 500 mg dans l'insuffisance veineuse fonctionnelle [in French]. J Int Med 1987;99:32-37.

Gilly, R., Pillion, G., and Frileux, C. Evaluation of a new venoactive micronized flavonoid fraction (S 5682) in symptomatic disturbances of the venolymphatic circulation of the lower limb: a double-blind, placebo-controlled study. Phlebology. 1994;9(2):67-70.

Menyhei, G., Acsady, G., Hetenyi, A., and et al. Chronobiology and clinical activity of Daflon 500 mg in chronic venous insufficiency. Phlebology. 1994;9(1):53-59.

Cospite, M. Double-blind, placebo-controlled evaluation of clinical activity and safety of Daflon 500 mg in the treatment of acute hemorrhoids. Drugs Today 1995;31(Suppl E):49-55.

Glinski, W, Chodynicka, B., Roszkiewicz, J., and et al. The beneficial augmentative effect of micronised purified flavonoid fraction (MPFF) on the healing of leg ulcers: an open, multicentre, controlled, randomised study. Phlebology. 1999;14(4):151-157.

Cho, YA, Choi, DH, and Choi, JS. Effect of hesperidin on the oral pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, in rats. J Pharm Pharmacol. 2009;61(6):825-829. View abstract.

Piao, YJ and Choi, JS. Enhanced bioavailability of verapamil after oral administration with hesperidin in rats. Arch Pharm Res. 2008;31(4):518-522. View abstract.

Giannini I, Amato A, Basso L, Tricomi N, Marranci M, Pecorella G, Tafuri S, Pennisi D, Altomare DF. Flavonoids mixture (diosmin, troxerutin, hesperidin) in the treatment of acute hemorrhoidal disease: a prospective, randomized, triple-blind, controlled trial. Tech Coloproctol. 2015 Jun;19(6):339-45. View abstract.

Andersen KE. Hesperidin methyl chalcone?-?a new cosmetic contact allergen. Contact Dermatitis. 2015;72(6):402-4. View abstract.

Demonty I, Lin Y, Zebregs YE, et al. The citrus flavonoids hesperidin and naringin do not affect serum cholesterol in moderately hypercholesterolemic men and women. J Nutr. 2010;140(9):1615-20. View abstract.

Martin BR, McCabe GP, McCabe L, et al. Effect of hesperidin with and without a calcium (Calcilock) supplement on bone health in postmenopausal women. J Clin Endocrinol Metab 2016;101(3):923-7. View abstract.

Milenkovic D, Deval C, Dubray C, et al. Hesperidin displays relevant role in the nutrigenomic effect of orange juice on blood leukocytes in human volunteers: a randomized controlled cross-over study. PLoS One 2011;6(11):e26669. View abstract.

Morand C, Dubray C, Milenkovic D, et al. Hesperidin contributes to the vascular protective effects of orange juice: a randomized crossover study in healthy volunteers. Am J Clin Nutr 2011;93(1):73-80. View abstract.

Ohara T, Muroyama K, Yamamoto Y, et al. Oral intake of a combination of glucosyl hesperidin and caffeine elicits an anti-obesity effect in healthy, moderately obese subjects: a randomized double-blind placebo-controlled trial. Nutr J 2016;15:6. View abstract.

Rizza S, Muniyappa R, Iantorno M, et al. Citrus polyphenol hesperidin stimulates production of nitric oxide in endothelial cells while improving endothelial function and reducing inflammatory markers in patients with metabolic syndrome. J Clin Endocrinol Metab 2011;96(5):E782-92. View abstract.

Homayouni F, Haidari F, Hedayati M, Zakerkish M, Ahmadi K. Blood pressure lowering and anti-inflammatory effects of hesperidin in type 2 diabetes; a randomized double-blind controlled clinical trial. Phytother Res. 2018;32(6):1073-1079. View abstract.

Martínez-Noguera FJ, Marín-Pagán C, Carlos-Vivas J, Rubio-Arias JA, Alcaraz PE. Acute Effects of Hesperidin in Oxidant/Antioxidant State Markers and Performance in Amateur Cyclists. Nutrients. 2019 Aug 14;11(8). pii: E1898. View abstract.

Cheraghpour M, Imani H, Ommi S, et al. Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo-controlled, double-blind clinical trial. Phytother Res. 2019 Aug;33(8):2118-2125. View abstract.

Lorzadeh E, Ramezani-Jolfaie N, Mohammadi M, Khoshbakht Y, Salehi-Abargouei A. The effect of hesperidin supplementation on inflammatory markers in human adults: A systematic review and meta-analysis of randomized controlled clinical trials. Chem Biol Interact. 2019 Jul 1;307:8-15. View abstract.

Mohammadi M, Ramezani-Jolfaie N, Lorzadeh E, Khoshbakht Y, Salehi-Abargouei A. Hesperidin, a major flavonoid in orange juice, might not affect lipid profile and blood pressure: A systematic review and meta-analysis of randomized controlled clinical trials. Phytother Res. 2019 Mar;33(3):534-545. View abstract.

Yari Z, Cheraghpour M, Alavian SM, Hedayati M, Eini-Zinab H, Hekmatdoost A. The efficacy of flaxseed and hesperidin on non-alcoholic fatty liver disease: an open-labeled randomized controlled trial. Eur J Clin Nutr. 2021;75(1):99-111. View abstract.

Yari Z, Cheraghpour M, Hekmatdoost A. Flaxseed and/or hesperidin supplementation in metabolic syndrome: an open-labeled randomized controlled trial. Eur J Nutr. 2021;60(1):287-298. View abstract.

Martínez-Noguera FJ, Marín-Pagán C, Carlos-Vivas J, Alcaraz PE. Effects of 8 weeks of 2S-hesperidin supplementation on performance in amateur cyclists. Nutrients. 2020;12(12):3911. View abstract.

Valls RM, Pedret A, Calderón-Pérez L, et al. Effects of hesperidin in orange juice on blood and pulse pressures in mildly hypertensive individuals: a randomized controlled trial (Citrus study). Eur J Nutr. 2021;60(3):1277-1288. View abstract.

Martínez Noguera FJ, Alcaraz PE, Carlos Vivas J, et al. 8 weeks of 2S-Hesperidin supplementation improves muscle mass and reduces fat in amateur competitive cyclists: randomized controlled trial. Food Funct. 2021;12(9):3872-3882. View abstract.

Djafari F, Shahavandi M, Amini MR, et al. The effects of hesperidin supplementation or orange juice consumption on anthropometric measures in adults: A meta-analysis of randomized controlled clinical trials. Clin Nutr ESPEN. 2021;43:148-157. View abstract.

Ohara T, Muroyama K, Yamamoto Y, Murosaki S. Erratum to: Oral intake of a combination of glucosyl hesperidin and caffeine elicits an antiobesity effect in healthy, moderately obese subjects: a randomized double-blind placebo-controlled trial. Nutr J. 2017;16(1):28. View abstract.

Yari Z, Movahedian M, Imani H, Alavian SM, Hedayati M, Hekmatdoost A. The effect of hesperidin supplementation on metabolic profiles in patients with metabolic syndrome: a randomized, double-blind, placebo-controlled clinical trial. Eur J Nutr. 2020;59(6):2569-2577. View abstract.

Miwa Y, Yamada M, Sunayama T, et al. Effects of glucosyl hesperidin on serum lipids in hyperlipidemic subjects: preferential reduction in elevated serum triglyceride level. J Nutr Sci Vitaminol (Tokyo). 2004;50(3):211-8. View abstract.

Homayouni F, Haidari F, Hedayati M, Zakerkish M, Ahmadi K. Hesperidin supplementation alleviates oxidative DNA damage and lipid peroxidation in type 2 diabetes: A randomized double-blind placebo-controlled clinical trial. Phytother Res. 2017;31(10):1539-1545. View abstract.

Bagnati M, Puricelli C, Bauce G, et al. Short-term effects of supplemental L-arginine, diosmin, troxerutin, and hesperidin in diabetic patients: A Pilot Study. Biomed Res Int 2021;2021:3508281. View abstract.

Yoshitomi R, Yamamoto M, Kumazoe M, et al. The combined effect of green tea and a-glucosyl hesperidin in preventing obesity: a randomized placebo-controlled clinical trial. Sci Rep 2021;11(1):19067. View abstract.